Antitumor activity of the WEE1 inhibitor AZD1775 as a monotherapy and in combination with the PARP inhibitor olaparib in patient-derived explant (PDX) models
M.J. O’Connor, J.F. Liu, John C. English(University of British Columbia Hospital), S. J. Powell, James William Thomas Yates, P. Jewsbury, Paul T. Kirschmeier(Brigham and Women's Hospital), J. Carl Barrett(National Institute of Environmental Health Sciences), Andrew Hughes(University of Minnesota), Anderson T. Wang(Lake Erie College of Osteopathic Medicine), Rajesh Odedra, Ursula A. Matulonis(Dana-Farber Cancer Institute), Sangeetha Palakurthi, Elena V. Ivanova(Massachusetts General Hospital), Andrew J. Pierce(Ouachita Baptist University), Brian Dougherty(AstraZeneca (United States)), Qing Zeng, Zhongwu Lai(AstraZeneca (United States)), S Dharma, Sihai Zhou
Cited by 3
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k